<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260179</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-80881-008</org_study_id>
    <nct_id>NCT03260179</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810</brief_title>
  <official_title>An Open-label Phase Ib, Study, to Determine Safety of Oral AL3810 in Patients With Locally Advanced or Metastatic Gastric, Hepatocellular or Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShangHai HaiHe Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ShangHai HaiHe Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project intends to make a study of personalized medicine evaluation system establishment
      for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the
      development of Precision Medicine and personalized medicine for the patients of
      high-incidence-rates cancer in China.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the number of patients with grade 3 and 4 AE according to CTC AE 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The proportion of patients who have observed overall remission (CR) or partial remission (PR) as the overall optimal remission based on the RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 3 cycles(28 days/cycle)</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 3 cycles(28 days/cycle)</time_frame>
    <description>Peak Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>All patients with the best overall response to CR or PR were required to calculate the duration of the response. This time is the duration (progression or death, whichever occurs first) from the first decision to CR or PR to tumor progression or death (death for any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>DCR refers to the percentage of patients who have achieved confirmation during the treatment of CR, confirmed PR and / or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>To the date of randomization to the date of the onset of the disease or the date of death (regardless of the cause of the death) (whichever is the earlier).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CD4+/CD8+</measure>
    <time_frame>from baseline up to six months(every 8 weeks±7 days )</time_frame>
    <description>cell count of CD4+/CD8+</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth factor</measure>
    <time_frame>from baseline up to six months(every 8 weeks±7 days ), C1D15</time_frame>
    <description>the content of growth factor such as VEGF，FGF and PDGF in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Exosomes</measure>
    <time_frame>from baseline up to six months(every 8 weeks±7 days )</time_frame>
    <description>the content of growth factor such as INFγ and cMyc in plasma</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Advanced/Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>gastric carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hepatocellular carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasopharyngeal carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL3810</intervention_name>
    <description>Fasting，oral ，4w on or 3w on/1w off</description>
    <arm_group_label>gastric carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL3810</intervention_name>
    <description>Fasting，oral ，4w on or 3w on/1w off</description>
    <arm_group_label>hepatocellular carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL3810</intervention_name>
    <description>Fasting，oral ，4w on or 3w on/1w off</description>
    <arm_group_label>Nasopharyngeal carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main criteria for inclusion:

          1. Adult male or female Chinese subject aged 18 to 70 years, inclusive, at the time of
             signing the informed consent form, with weight at least 40 kg when screening.

          2. Life expectancy ≥ 12 weeks as judged by the Investigator.

          3. Histologically or cytologically confirmed, locally advanced or metastatic solid tumor
             and be limited to:

               -  Gastric carcinoma (including gastro-oesophageal junction adenocarcinoma).

               -  Hepatocellular carcinoma (Child-Pugh Class A).

               -  Undifferentiated nasopharyngeal carcinoma.

          4. Each subject should provide at least 5 slides for the formalin fixed and paraffin
             embedded tumor biopsy (undyed) at the baseline, fresh biopsy or most recent primary
             tumor sample or metastatic sample is required.

          5. Patients, who have progressed on (or not been able to tolerate) standard therapy or
             for whom no standard anticancer therapy exists.

          6. Toxicities from any prior therapy, surgery, or radiotherapy must have resolved to
             Grade ≤ 1 as per the National Cancer Institute- Common Terminology Criteria for
             Adverse Events (NCI-CTCAE), excluding alopecia and peripheral neuropathy. For subjects
             having a prior platinum-based therapy, peripheral neuropathy are required to recover
             to ≤ CTCAE grade 2.

          7. Per RECIST v1.1 guidelines for solid tumors:

               -  Patients with gastric carcinoma should have at least one measurable lesion beyond
                  stomach,

               -  Patients with Hepatocellular carcinoma and undifferentiated nasopharyngeal
                  carcinoma should have at least one measurable lesion.

          8. Adequate bone marrow and organ function as defined by the following laboratory values:
             (prophylactic use of myeloid growth factors (eg, G-CSF, GM-CSF) is prohibited within 2
             weeks before screening)

               -  Absolute neutrophil count (ANC) ≥ 1.5x 109/L.

               -  Platelet counts ≥ 100 x 109/L.

               -  Haemoglobin ≥ 90 g/L (without blood transfusion within the last 2 weeks from
                  screening).

               -  Creatinine clearance &gt; 50 mL/min (calculated according to Cockroft-Gault
                  formula).

               -  Proteinuria &lt; 1+. If proteinuria ≥ 1+, urine protein quantitation over 24 hours
                  should be &lt; 1.0 g/24hrs.

               -  INR ≤ 1.5 and APTT≤ 1.5 Upper Limit of Normal (ULN).

               -  AST, ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases or hepatocellular carcinomas
                  are present).

               -  Total Bilirubin &lt; 1.5 x ULN.

               -  For Hepatocellular carcinomas patients, albumin ≥ 28 g/dL.

          9. Patient has an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1.

         10. Patient is able to swallow and retain oral medication.

         11. Female subjects, with childbearing potential, has a negative serum pregnancy test at
             screening (within 7 days of the first investigational product administration). The
             definition of women with child-bearing potential are defined as &quot;All female subjects
             after puberty unless they are post-menopausal or not sexually active&quot;. Females are
             considered postmenopausal if they have age-related amenorrhea ≥ 12 consecutive months
             or if they have undergone hysterectomy or bilateral oophorectomy.

         12. Patients who have fully understood the study, and have signed the general Informed
             Consent Form (ICF) prior to any screening procedures being performed

        Main criteria for non-inclusion

          1. Patient who has participated in another interventional trial within 28 days prior to
             starting study medicine. If a subject is joining a non-interventional trial, such as
             an epidemiological study, or in a survival follow-up period of an interventional
             trial, he or she may participate in this trial.

          2. Expected poor compliance during the study.

          3. Patient has symptomatic CNS metastases requiring clinical intervention. The stable
             patient may participate in this trial, who must have completed any prior local
             treatment for CNS metastases ≥ 14 days prior to the start of study treatment
             (including radiotherapy and/or low dose steroid therapy).

          4. Patient has a concurrent malignancy or malignancy within 2 years of study enrolment,
             with the exception of adequately treated and cured non-melanomatous skin cancer,
             carcinoma in situ of breast and cervix, and superficial bladder cancer.

          5. Patient who has received chemotherapy, targeted therapy or immunotherapy within 28
             days or ≤ 5 half-lives prior to starting study medicine. Take the longer one. For HCC
             patient who has received any prior local therapy (hepatic arterial embolization,
             transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation,
             percutaneous ethanol injection or cryoablation) within 4 weeks of starting study
             medicine •.

          6. Previous treatment with Bevacizumab within 3 months of starting AL3810. In addition:

             - Patients with nasopharyngeal carcinoma who received antiangiogenic agent are not
             allowed.

          7. Patients with nasopharyngeal carcinoma located within 5mm of large blood vessels.

          8. Patient who has received wide field radiotherapy within 28 days prior to starting
             study medicine

          9. Patient who has received a major surgery within 28 days prior to starting study
             medicine. The definition of a major surgery refers to grade 3 and 4 surgery specified
             in &lt;Management of Clinical Practice of Medical Technologies&gt; effective on May 1, 2009
             in China,

         10. Patient has active cardiac disease or a history of cardiac dysfunction in screening
             including any of the following:

               -  History of documented Congestive heart failure ≥ class II (NYHA New York Heart
                  Association functional classification) or requiring therapy,

               -  Ventricular and/or supraventricular arrhythmia requiring therapy;

               -  Severe conduction disturbance (including QTc interval prolongation &gt; 450msec
                  [corrected by Fredericia formula], history of severe arrhythmia, or history of
                  familial arrhythmia [e.g., Wolff-Parkinson-White syndrome]),

               -  Angina pectoris requiring therapy,

               -  Left ventricular ejection fraction (LVEF) &lt; 50% evaluated by cardiac ultrasound
                  (ECHO) or Multi Gated Acquisition Scan (MUGA) ,

               -  Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 140mmHg
                  and/or diastolic blood pressure ≥ 90mmHg with optimized antihypertensive therapy
                  or patients treated with ≥ 2 antihypertensive agents),

               -  Hypertension with systolic blood pressure ≥ 160mmHg and/or diastolic blood
                  pressure ≥ 100mmHg with or without antihypertensive therapy.

               -  Conduction abnormality requiring a pacemaker or implanted a pacemaker.

         11. History of clinically significant or uncontrolled cardiac disease within 6 months
             prior to starting AL3810, including angina, myocardial infarction, and stroke.

         12. Patients with thromboembolic events within 12 months prior to starting AL3810, or at a
             high risk of such events.

         13. Patient with hereditary risks of thromboembolic events.

         14. Patient is currently receiving treatment with warfarin or any other oral
             Anticoagulants

         15. Patients with active HBV or HCV infection or known positivity for human
             immunodeficiency virus (HIV) infection are not allowed. HBV, HCV and HIV will be
             tested in the screening. Serum HBsAg positive with HBV DNA &lt;104 Copy/mL may
             participate study. Prophylactic anti-HBV medications application can be accepted.
             Serum HCV or HIV antibody positive is not allowed.

         16. Patients receiving medications known to prolong QTc interval and that may be
             associated with Torsades de Pointes.

         17. Serum potassium (K+) levels below LLN at screening period.

         18. Patients who received administration of strong inhibitors of CYP2C8 and/or CYP3A4 or
             strong inducers of CYP3A4 within 7 days or ≤ 5 half-lives (Take the longer one) prior
             to starting AL3810. And patient cannot stop taking the medication. .

         19. Significant gastrointestinal abnormalities, including ulcerative colitis, chronic
             diarrhoea associated with intestinal malabsorption, the Crohn's disease, or
             significant abnormalities decided by investigator. In addition, patients with any
             grade of gastro-intestinal bleeding events within 3 months prior to starting AL3810
             are not allowed.

         20. History of grade 3 haemorrhage/bleeding events within 6 months prior to starting
             AL3810, or history of grade 4 haemorrhage/bleeding events.

         21. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis,
             thyroid and adrenal gland.

         22. Serious/active bacterial, viral or fungal infection requiring systemic treatment.

         23. Concomitant uncontrolled severe systemic disease (e.g., uncontrolled diabetes
             mellitus, uncontrolled ascites, etc.).

         24. Psychiatric disorder or altered mental status that would preclude understanding of the
             informed consent process and/or completion of the necessary study procedures.

         25. Known organ dysfunction which would either compromise the patient's safety or
             interfere with the evaluation of AL3810.

         26. Male patients and female patients of child bearing potential unable or unwilling to
             employ effective contraception (abstinence, barrier method with spermicide,
             intrauterine device, or steroidal contraceptive for women and barrier method) during
             the study and for 6 months thereafter.

         27. Breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Shu kui, MD</last_name>
    <phone>13905158713</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Hai qing, MD</last_name>
    <phone>13951807023</phone>
    <email>huahaiqing@csco.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 307th Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Jian ming, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Rui hua, MD</last_name>
      <phone>13922206676</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang li, MD</last_name>
      <phone>13902282893</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 81st Hospital of People's Liberation Army</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Shu kui, MD</last_name>
      <phone>13905158713</phone>
      <email>qinsk@csco.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Ji feng, MD</last_name>
      <phone>13901581264</phone>
      <email>fjif@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao Jun ning, MD</last_name>
      <phone>13651680209</phone>
      <email>cao_junning@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

